Intro::Tuberculosis management


Journal::title    Issue::volume    Pages::author    Patients::drugs    Ndash::months    Should::patient

{{#invoke:redirect hatnote|redirect}}

Various pharmaceutical tuberculosis treatments and their actions

Tuberculosis treatment refers to the medical treatment of the infectious disease tuberculosis (TB).

The standard "short" course treatment for TB is isoniazid (along with pyridoxal phosphate to obviate peripheral neuropathy caused by isoniazid), rifampicin (also known as rifampin in the United States), pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered to be free of living bacteria after six months (although there is still a relapse rate of up to 7%). For latent tuberculosis, the standard treatment is six to nine months of daily isoniazid alone or three months of weekly (12 doses total) of isoniazid/rifapentine combination. <ref>Sterling, T. R., Villarino, M. E., Borisov, ... & Chaisson, R. E. (2011). Three months of rifapentine and isoniazid for latent tuberculosis infection. New England Journal of Medicine, 365(23), 2155-2166</ref><ref>World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World Health Organization; 2015.</ref> If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by isoniazid and rifampicin for four months. Ethambutol need not be used.

Tuberculosis management sections
Intro  Drugs  The standard regimen  Non-compliance  Adverse effects  Deviations from the standard regimen  Tuberculosis and other conditions  Drug-resistant tuberculosis  Treatment failure  Treatment relapse  Society and culture  Trial of therapy  Surgical treatment  Nutrition  Latent tuberculosis  Current research  See also  National and international guidelines   Bibliography